Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities
作者：Yewei Yang, Nian-Hua Deng, Kai-Jiang Tian, Lu-Shan Liu, Zuo Wang, Dangheng Wei, Huiting Liu, Zhisheng Jiang · 发表于：Frontiers in Cardiovascular Medicine · 年份：2022 · DOI：10.3389/fcvm.2022.909178 · 被引用次数：19 · 研究领域：Sulfur Compounds in Biology、Eicosanoids and Hypertension Pharmacology、Mast cells and histamine
Hydrogen sulfide (H<sub>2</sub>S), a gas transmitter found in eukaryotic organisms, plays an essential role in several physiological processes. H<sub>2</sub>S is one of the three primary biological gas transmission signaling mediators, along with nitric oxide and carbon monoxide. Several animal and <i>in vitro</i> experiments have indicated that H<sub>2</sub>S can prevent coronary endothelial mesenchymal transition, reduce the expression of endothelial cell adhesion molecules, and stabilize intravascular plaques, suggesting its potential role in the treatment of atherosclerosis (AS). H<sub>2</sub>S donors are compounds that can release H<sub>2</sub>S under certain circumstances. Development of highly targeted H<sub>2</sub>S donors is a key imperative as these can allow for in-depth evaluation of the anti-atherosclerotic effects of exogenous H<sub>2</sub>S. More importantly, identification of an optimal H<sub>2</sub>S donor is critical for the creation of H<sub>2</sub>S anti-atherosclerotic prodrugs. In this review, we discuss a wide range of H<sub>2</sub>S donors with anti-AS potential along with their respective transport pathways and design-related limitations. We also discuss the utilization of nano-synthetic technologies to manufacture H<sub>2</sub>S donors. This innovative and effective design example sheds new light on the production of highly targeted H<sub>2</sub>S donors.